Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 328-337 , June 2010

Symptom complaints of patients prescribed either oral methadone or injectable heroin

  • Kenneth M. Dürsteler-MacFarland, M.A.

      Affiliations

    • Psychiatric Hospital of the University of Basel, Division of Substance Use Disorders, 4025 Basel, Switzerland
    • Psychiatric University Hospital Zurich, Division of Substance Use Disorders, 8002 Zurich, Switzerland
    • Corresponding Author InformationCorresponding author. Psychiatric Hospital of the University of Basel, Wilhelm Klein-Strasse 27, CH-4025 Basel, Switzerland. Tel.: +41 61 325 5125; fax: +41 61 325 5364.
    • These authors contributed equally to this study.
    • ,
  • Dominique A. Fischer, Med. Pract

      Affiliations

    • Psychiatric Hospital of the University of Basel, Division of Substance Use Disorders, 4025 Basel, Switzerland
    • These authors contributed equally to this study.
    • ,
  • Sandra Mueller, M.Sc.

      Affiliations

    • Psychiatric Hospital of the University of Basel, Division of Substance Use Disorders, 4025 Basel, Switzerland
    • ,
  • Otto Schmid, M.A.

      Affiliations

    • Psychiatric Hospital of the University of Basel, Division of Substance Use Disorders, 4025 Basel, Switzerland
    • ,
  • Andreas Moldovanyi, Dr. Med.

      Affiliations

    • Psychiatric University Hospital Zurich, Division of Substance Use Disorders, 8002 Zurich, Switzerland
    • Polyclinics for Heroin Prescription Lifeline/Crossline, City Medical Services, 8001 Zurich, Switzerland
    • ,
  • Gerhard A. Wiesbeck, Dr. Med.

      Affiliations

    • Psychiatric Hospital of the University of Basel, Division of Substance Use Disorders, 4025 Basel, Switzerland

Received 10 July 2009 ,Revised 11 January 2010 ,Accepted 15 January 2010.

References 

  1. Act-Info . Nationale Substitutionsstatistik (Methadon): Federal Office of Public Health. Available at http://www.nasuko.ch/nms/db/index.cfm2007;
  2. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment. 2005;28:321–329
  3. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: Patients, programs, services, and outcome. New York: Springer Verlag; 1991;
  4. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287:622–627
  5. Bell J, Mattick R, Hay A, Chan J, Hall W. Methadone maintenance and drug-related crime. Journal of Substance Abuse. 1997;9:15–25
  6. Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: A randomized, controlled trial. Annals of Internal Medicine. 2006;144:257–261
  7. Blattler R, Dobler-Mikola A, Steffen T, Uchtenhagen A. Decreasing intravenous cocaine use in opiate users treated with prescribed heroin. Sozial-und Präventivmedizin. 2002;47:24–32
  8. Brown BS, Benn GJ, Jansen DR. Methadone maintenance: Some client opinions. American Journal of Psychiatry. 1975;132:623–626
  9. Brown R, Balousek S, Mundt M, Fleming M. Methadone maintenance and male sexual dysfunction. Journal of Addictive Diseases. 2005;24:91–106
  10. Bruera E, Macmillan K, Selmser P, MacDonald RN. Decreased local toxicity with subcutaneous diamorphine (heroin): A preliminary report. Pain. 1990;43:91–94
  11. Bundesrat . Botschaft zum Bundesgesetz über die Verlängerung des Bundesbeschlusses über die ärztliche Verschreibung von Heroin. Available at http://www.admin.ch/ch/d/ff/2002/5839.pdf2002;
  12. Caplehorn JR, Irwig L, Saunders JB. Physicians' attitudes and retention of patients in their methadone maintenance programs. Substance Use and Misuse. 1996;31:663–677
  13. Clark JD, Elliott J. A case of a methadone-induced movement disorder. The Clinical Journal of Pain. 2001;17:375–377
  14. D'Aunno T, Pollack HA. Changes in methadone treatment practices: Results from a national panel study, 1988–2000. JAMA. 2002;288:850–856
  15. D'Aunno T, Vaugh TE. Variations in methadone treatment practices. Results from national study. JAMA. 1992;267:253–258
  16. Davoli M, Perucci CA, Forastiere F, Doyle P, Rapiti E, Zaccarelli M, et al. Risk factors for overdose mortality: A case-control study within a cohort of intravenous drug users. International Journal of Epidemiology. 1993;22:273–277
  17. De Amici D, Klersy C, Ramajoli F, Brustia L, Politi P. Impact of the Hawthorne effect in a longitudinal clinical study: The case of anesthesia. Controlled Clinical Trials. 2000;21:103–114
  18. Dürsteler-MacFarland KM, Stohler R, Moldovanyi A, Rey S, Basdekis R, Gschwend P, et al. Complaints of heroin-maintained patients: A survey of symptoms ascribed to diacetylmorphine. Drug and Alcohol Dependence. 2006;81:231–239
  19. Dürsteler-MacFarland KM, Störmer R, Seifritz E, Hug I, Müller-Spahn F, Ladewig D, et al. Opioid-associated effects on oxygen saturation in humans. Addiction. 2000;95:285–287
  20. Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: High frequency in hospitalized patients and risk factors. Archives of Internal Medicine. 2006;166:1280–1287
  21. Florez J, Mediavilla A. Respiratory and cardiovascular effects of met-enkephalin applied to the ventral surface of the brain stem. Brain Research. 1978;138:585–590
  22. FOPH—Federal Office of Public Health . Heroin-assisted treatment/treatment with diacetylmorphine (HAT) in 2006. Available at http://www.bag.admin.ch/themen/drogen/00042/00629/00798/01191/index.html?lang=en2007;
  23. French MT, Zarkin GA, Hubbard RL, Rachal JV. The effects of time in drug abuse treatment and employment on posttreatment drug use and criminal activity. American Journal of Drug and Alcohol Abuse. 1993;19:19–33
  24. Goldsmith DS, Hunt DE, Lipton DS, Strug DL. Methadone folklore: Beliefs about side effects and their impact on treatment. Human Organization. 1984;43:330–340
  25. Graham CH, Meechan JG. Dental management of patients taking methadone. Dental Update. 2005;32:477–485
  26. Grönbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: Impact of methadone treatment. Acta Psychiatrica Scandinavia. 1990;83:223–227
  27. Gupta R, Haydock T. Severe hypercapnia caused by acute heroin overdose. Annals of Emergency Medicine. 2004;43:665–666
  28. Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: Two decades of experience in the Bronx, New York City. Journal of Public Health Reports. 1998;113(Suppl. 1):107–115
  29. Hubbard RL, Marsden ME, Rachal JV, Harwood HJ, Cavangh ER, Ginzburg HM. Drug abuse treatment: A national study of effectiveness. Carey: University of North Carolina Press; 1989;
  30. Hunt DE, Lipton DS, Goldsmith DS, Strug DL, Spunt B. “It takes your heart”: The image of methadone maintenance in the addict world and its effect on recruitment into treatment. International Journal of the Addictions. 1985;20:1751–1771
  31. Judson BA, Goldstein A. Symptom complaints of patients maintained on methadone, LAAM (methadyl acetate), and naltrexone at different times in their addiction careers. Drug and Alcohol Dependence. 1982;10:269–282
  32. Kayman DJ, Goldstein MF, Deren S, Rosenblum A. Predicting treatment retention with a brief “Opinions About Methadone” scale. Journal of Psychoactive Drugs. 2006;38:93–100
  33. Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of methadone on QT-interval dispersion. Pharmacotherapy. 2005;25:1523–1529
  34. Kreek MJ, Hartman N. Chronic use of opioids and antipsychotic drugs: Side effects, effects on endogenous opioids, and toxicity. Annals of the New York Acadademy of Science. 1982;398:151–172
  35. Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: Blending conference session. Journal of Substance Abuse Treatment. 2002;23:93–105
  36. Longwell B, Kestler RJ, Cox TJ. Side effects in methadone patients: A survey of self-reported complaints. The International Journal of the Addictions. 1979;14:485–494
  37. Magura S, Rosenblum A. Leaving methadone treatment: Lessons learned, lessons forgotten, lessons ignored. The Mount Sinai Journal of Medicine. 2001;68:62–74
  38. Martin JE, Inglis J. Pain tolerance and narcotic addiction. The Brithish Journal of Social and Clinical Psychology. 1965;4:224–229
  39. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;(2):CD002209
  40. Mercadante S, Villari P, Fulfaro F. Gabapentin for opioid-related myoclonus in cancer patients. Supportive Care in Cancer. 2001;9:205–206
  41. Mintz J, O'Hare K, O'Brien CP, Goldschmidt J. Sexual problems of heroin addicts. Archives of General Psychiatry. 1974;31:700–703
  42. Moldovanyi A, Ladewig D, Affentranger P, Natsch C, Stohler R. Morphine maintenance treatment of opioid-dependent out-patients. European Addiction Research. 1996;2:208–212
  43. Morabia A, Fabre J, Chee E, Zeger S, Orsat E, Robert A. Diet and opiate addiction: A quantitative assessment of the diet of non-institutionalized opiate addicts. British Journal of Addiction. 1989;84:173–180
  44. Nolan LJ, Scagnelli LM. Preference for sweet foods and higher body mass index in patients being treated in long-term methadone maintenance. Substance Use and Misuse. 2007;42:1555–1566
  45. Nordt C, Stohler R. Incidence of heroin use in Zurich, Switzerland: A treatment case register analysis. The Lancet. 2006;367:1830–1834
  46. Novick DM, Richman BL, Friedman JM, Friedman JE, Fried C, Wilson JP, et al. The medical status of methadone maintenance patients in treatment for 11–18 years. Drug and Alcohol Dependence. 1993;33:235–245
  47. Peles E, Bodner G, Kreek MJ, Rados V, Adelson M. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: A cross-sectional study. Addiction. 2007;102:289–300
  48. Peles E, Schreiber S, Adelson M. Variables associated with perceived sleep disorders in methadone maintenance treatment (MMT) patients. Drug and Alcohol Dependence. 2006;82:103–110
  49. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511–2518
  50. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. The Lancet. 2001;358:1417–1423
  51. Rook EJ, van Zanten AP, Van den Brink W, van Ree JM, Beijnen JH. Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin. Drug and Alcohol Dependence. 2006;85:185–190
  52. Rosenblum A, Magura S, Joseph H. Ambivalence toward methadone treatment among intravenous drug users. Journal of Psychoactive Drugs. 1991;23:21–27
  53. Santiago TV, Pugliese AC, Edelman NH. Control of breathing during methadone addiction. The American Journal of Medicine. 1977;62:347–354
  54. Sarhill N, Davis MP, Walsh D, Nouneh C. Methadone-induced myoclonus in advanced cancer. The American Journal of Hospice and Palliative Care. 2001;18:51–53
  55. Schmittner J, Schroeder JR, Epstein DH, Preston KL. Menstrual cycle length during methadone maintenance. Addiction. 2005;100:829–836
  56. Sepelloni G, Carrierei MP, Rezza G, Morganti S, Gomma M, Binkin N. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: A nested case-control study. AIDS Care. 1994;6:215–220
  57. Simpson DD. The relation of time spent in drug abuse treatment to posttreatment outcome. American Journal of Psychiatry. 1979;136:1449–1453
  58. Simpson DD, Savage LJ, Lloyd MR. Follow-up evaluation of treatment of drug abuse during 1969 to 1972. Archives of General Psychiatry. 1979;36:772–780
  59. SSAM―Swiss Society of Addiction Medicine. Clinical recommendations for substitution-assisted treatment in opioid dependence. Available at http://www.ssam.ch/SSAM/en/Clinical%20Recommendations2007;
  60. Stancliff S, Myers JE, Steiner S, Drucker E. Beliefs about methadone in an inner-city methadone clinic. Journal of Urban Health. 2002;79:571–578
  61. Stoermer R, Drewe J, Dürsteler-MacFarland K, Ladewig D, Hock C, Müller-Spahn F, et al. Safety of injectable opioid treatment in addiction: A controlled clinical trial. Biological Psychiatry. 2003;54:854–861
  62. Strike CJ, Gnam W, Urbanoski K, Fischer B, Marsh DC, Millson M. Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. Addictive Behaviors. 2005;30:1025–1028
  63. Uchtenhagen A, Gutzwiller F, Dobler-Mikola A, Steffen T. Programme for a medical prescription of narcotics: A synthesis of results. European Addiction Research. 1997;3:160–163
  64. Uehlinger C, Hauser C. Allergic reactions from injectable methadone. American Journal of Psychiatry. 1999;156:973
  65. WHO . The ICD-10 Classification of Mental and Behavioural Disorders, Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992;
  66. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. The Lancet. 1999;353:221–226
  67. Warner LA, Kessler RC, Hughes M, Anthony JC, Nelson CB. Prevalence and correlates of drug use and dependence in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry. 1995;52:219–229
  68. Zador D, Lyons Wall PM, Webster I. High sugar intake in a group of women on methadone maintenance in south western Sydney, Australia. Addiction. 1996;91:1053–1061
  69. Zule WA, Desmond DP. Attitudes toward methadone maintenance: Implications for HIV prevention. Journal of Psychoactive Drugs. 1998;30:89–97

PII: S0740-5472(10)00016-4

doi: 10.1016/j.jsat.2010.01.008

Journal of Substance Abuse Treatment
Volume 38, Issue 4 , Pages 328-337 , June 2010

Article Tools